Xin Lang Cai Jing·2025-11-27 07:21Core Viewpoint - The company, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a strong overseas revenue base [2][3]. Company Overview - Shenzhen Hepalink was established in 1998 and has dual financing platforms (A+H shares), primarily engaged in the research, production, and sales of heparin sodium raw materials and downstream low molecular weight heparin products [7]. - The company's main business revenue composition includes: formulations (63.06%), CDMO (18.59%), heparin sodium and low molecular weight heparin raw materials (16.05%), and others (2.30%) [7]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 4.194 billion yuan, representing a year-on-year growth of 3.09%, while the net profit attributable to the parent company was 554 million yuan, a decrease of 29.04% year-on-year [7]. - As of September 30, 2025, the company had a total of 27,000 shareholders, an increase of 2.60% from the previous period [7]. Market Activity - On November 27, the company's stock price fell by 1.43%, with a trading volume of 35.8725 million yuan and a turnover rate of 0.24%, resulting in a total market capitalization of 17.153 billion yuan [1]. - The company has seen a net outflow of 2.5375 million yuan from major funds today, with a ranking of 79 out of 159 in its industry [4][5]. Dividend Information - Since its A-share listing, the company has distributed a total of 4.21 billion yuan in dividends, with 514 million yuan distributed over the past three years [8]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the eighth largest circulating shareholder, holding 12.0093 million shares, an increase of 691,700 shares from the previous period [9].